 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
New Alzheimer’s Disease Treatment StudyThe Boston University Alzheimer’s Disease Center (BU ADC) is pleased to announce its involvement in a new multi-center, Phase III study to examine a potential treatment for mild to moderate Alzheimer’s disease (AD). The study, referred to as “Interrupting Alzheimer’s Dementia by Evaluating Treatment of Amyloid Pathology,” or “IDENTITY,” will compare two doses of an experimental medication, LY450139. LY450139 was developed by Eli Lilly and Company. LY450139 inhibits the action of the enzyme gamma secretase in order to reduce amyloid beta (Abeta). Abeta clumps together in the brains of AD patients to create amyloid plaques, which are thought to be the initial cause of AD. The IDENTITY study will investigate whether LY450139, compared to a placebo or sugar pill, slows the rate of AD progression by examining cognitive and functional abilities among study participants. Though some participants will receive a placebo at the beginning of the study, all participants will eventually receive the active drug LY450139 before the end of the study. However, the exact timing of when the placebo will be switched to the active drug will be unknown to both the participants and study investigators. The IDENTITY study is seeking participants who are medically stable, over 55 years of age, and have a diagnosis of probable AD. All participants should have a caregiver who is in frequent contact with the participant and who will monitor the administration of medications. For more information about this study, please contact Ms. Stephanie Sikora at 617-414-1078 or sasikora@bu.edu. |
|
 |
 |
 |
 |
 |
|